ArticleBiology of reproduction2012
1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model.
Article in Biology of reproduction, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07647198 (FATIMA Trial), which is not on this map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
FATIMA Trial: EGCG and Vitamin D3 for Secondary Prevention of Uterine Fibroids
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it, 154 citations in OpenAlex.
- Correlation of low serum vitamin-D with uterine leiomyoma: a systematic review and meta-analysis.Reproductive biology and endocrinology : RB&E · 2020Pooled it
- Vitamin D and assisted reproduction technologies: current concepts.Reproductive biology and endocrinology : RB&E · 2014Pooled it
- Hypovitaminosis D and "small burden" uterine fibroids: Opportunity for a vitamin D supplementation.Medicine · 2016Trial
- Review
- Review
- Vitamin D and Uterine Fibroids: Insights into Pathophysiology and Therapeutic Potential.Endocrine reviews · 2026Review
- Preclinical research platform for uterine leiomyoma: construction optimization and selection of animal models.Frontiers in veterinary science · 2026Article
- The epidemiology and pathogenesis of uterine fibroids.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Review
- The Potential of Vitamin D and Epigallocatechin Gallate (EGCG) for the Treatment of Uterine Fibroids: Evidence From In Vitro to Clinical Studies.Molecular nutrition & food research · 2025Review
- Increased risk of uterine leiomyoma among women with migraine in reproductive age.Scientific reports · 2025Article
- A Prospective Ultrasound Study of Whole Blood Metals and Incidence of Uterine Leiomyomata.Environmental health perspectives · 2025Article
- Emerging perspectives: unraveling the anticancer potential of vitamin DNaunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Epigallocatechin Gallate for the Treatment of Benign and Malignant Gynecological Diseases-Focus on Epigenetic Mechanisms.Nutrients · 2024Review
- Review
- Evidence-Based Approach for Secondary Prevention of Uterine Fibroids (The ESCAPE Approach).International journal of molecular sciences · 2023Review
- Increased Occurrence of Cutaneous Leiomyomas and Dermatofibromas in Patients with Uterine Leiomyomas without Fumarate Hydratase Gene Mutations.Dermatopathology (Basel, Switzerland) · 2023Article
- Progesterone Signaling and Uterine Fibroid Pathogenesis; Molecular Mechanisms and Potential Therapeutics.Cells · 2023Review
- The effect of calcitriol on the development and implantation capacity of embryos from hyper-stimulated mice.Frontiers in immunology · 2023Article
- Vitamin D and uterine fibroid growth, incidence, and loss: a prospective ultrasound study.Fertility and sterility · 2022Article
- Transcriptome and DNA methylome analyses reveal underlying mechanisms for the racial disparity in uterine fibroids.JCI insight · 2022Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Uterine leiomyomas (fibroids) are the most common benign tumors in women of reproductive age. These tumors are three to four times more prevalent in African American women, who also have a 10 times higher incidence of hypovitaminosis D than white women. Recent studies have demonstrated the antitumor effects of 1,25-dihydroxyvitamin D3 on several cancers, but its effects on uterine leiomyomas are still unknown. To determine the antitumor and therapeutic effects of 1,25-dihydroxyvitamin D3 on uterine leiomyomas, female Eker rats (14-16 mo old) harboring uterine leiomyomas were randomized into control and experimental groups and were given vehicle versus 1,25-dihydroxyvitamin D3 (0.5 μg/kg per day) subcutaneously for 3 wk, respectively. At the end of the experiment, the rats were euthanized, and the leiomyoma tumors were analyzed. Treatment with 1,25-dihydroxyvitamin D3 significantly reduced leiomyoma tumor size in Eker rats. It also reduced leiomyoma size by suppressing cell growth and proliferation-related genes (Pcna, cyclin D1 [Ccnd1], Myc, Cdk1, Cdk2, and Cdk4), antiapoptotic genes (Bcl2 and Bcl2l1 [Bcl-x]), and estrogen and progesterone receptors. Additionally, immunohistochemistry revealed decreased expression of PCNA and MKI67 (a marker of proliferation) and increased expression of caspase 3 in 1,25-dihydroxyvitamin D3-treated Eker rat leiomyomas. Toxicity analyses using serum samples showed similar levels of SGOT, SGPT, calcium, and total bilirubin in 1,25-dihydroxyvitamin D3-treated and vehicle-treated control Eker rats. These results support that 1,25-dihydroxyvitamin D3 is an antitumor agent that may be a potential safe, nonsurgical therapeutic option for the treatment of uterine leiomyomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.